ursodeoxycholic acid has been researched along with Alcoholic Fatty Liver in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Andreev, V; Belonovskaya, E; Bergler, S; Büchele, B; Buckert, D; Buko, V; Diesinger, T; Dvorsky, R; Günes, C; Haehner, T; Kirko, S; Kuchenbauer, F; Kumar, M; Lautwein, A; Lukivskaya, O; Müller-Enoch, D; Naruta, E; Renz, C; Schneider, E; Simmet, T; Wirth, T | 1 |
| Abakumov, VZ; Belonovskaia, EB; Buko, VU; Lukivskaia, OIa; Naruta, EE | 1 |
| Carr, RM; Reid, AE | 1 |
| Kang, YZ; Liu, YH; Shen, ZY; Sun, XY | 1 |
| He, P; Lei, JH; Wang, CX; Yuan, WG; Zhang, CY | 1 |
| Dufour, JF; Oneta, CM | 1 |
| Buko, V; Knas, M; Lukivskaya, O; Zavodnik, L | 1 |
| Beaugé, F; Choquart, D; Guitaoui, M; Montet, AM; Montet, JC; Oliva, L | 1 |
| Andrade, RJ; García-Escaño, MD | 1 |
| Buko, VU; Lukivskaya, OY; Maskevich, AA | 1 |
| Blechacz, B; Herrmann, T; Mueller, S; Rost, D; Stremmel, W | 1 |
4 review(s) available for ursodeoxycholic acid and Alcoholic Fatty Liver
| Article | Year |
|---|---|
FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.
Topics: Bile Acids and Salts; Chenodeoxycholic Acid; Cholagogues and Choleretics; Fatty Liver, Alcoholic; Humans; NF-kappa B; Non-alcoholic Fatty Liver Disease; Phosphoenolpyruvate Carboxykinase (ATP); PPAR alpha; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Ursodeoxycholic Acid | 2015 |
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; CD4-Positive T-Lymphocytes; Disease Progression; Fatty Liver, Alcoholic; Hepatic Stellate Cells; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Liver Cirrhosis; Macrophages; MicroRNAs; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Resveratrol; Schistosomiasis; Signal Transduction; Stilbenes; T-Lymphocytes, Regulatory; Triterpenes; Ursodeoxycholic Acid; Ursolic Acid; Virus Diseases | 2016 |
[Alcoholic and non-alcoholic steatohepatitis].
Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver, Alcoholic; Gemfibrozil; Hepatitis; Hepatitis, Alcoholic; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Liver Transplantation; Middle Aged; Obesity; Pilot Projects; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography; Ursodeoxycholic Acid; Weight Loss | 2004 |
[Therapy of alcoholic and non-alcoholic fatty liver].
Topics: Anti-Infective Agents; Antioxidants; Cholagogues and Choleretics; Clinical Trials as Topic; Diagnosis, Differential; Diet, Reducing; Exercise; Fatty Liver; Fatty Liver, Alcoholic; Hepatitis, Alcoholic; Humans; Hypolipidemic Agents; Lipotropic Agents; Liver Cirrhosis; Liver Function Tests; Risk Factors; Ursodeoxycholic Acid | 2001 |
8 other study(ies) available for ursodeoxycholic acid and Alcoholic Fatty Liver
| Article | Year |
|---|---|
Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.
Topics: Alkanes; Animals; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP2E1 Inhibitors; Fatty Liver, Alcoholic; Female; Hep G2 Cells; Humans; Lipoproteins, VLDL; Liver; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Severity of Illness Index; Triglycerides; Ursodeoxycholic Acid | 2020 |
[Preventive administration of new UDCA derivatives in experimental alcoholic steatohepatitis].
Topics: Acetylcysteine; Alkaline Phosphatase; Animals; Cholagogues and Choleretics; Diet; Ethanol; Fatty Liver, Alcoholic; Female; gamma-Glutamyltransferase; Liver; Protective Agents; Rats; Rats, Wistar; Triglycerides; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid | 2013 |
Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation.
Topics: Cholagogues and Choleretics; Cholestasis; Fatty Liver, Alcoholic; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Prednisone; Tacrolimus; Treatment Outcome; Ursodeoxycholic Acid | 2015 |
[Gastroenterology and hepatology. Using established therapies].
Topics: Anti-Inflammatory Agents; Clinical Trials as Topic; Colitis, Ulcerative; Combined Modality Therapy; Crohn Disease; Evidence-Based Medicine; Fatty Liver, Alcoholic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Mesalamine; Ursodeoxycholic Acid; Weight Loss | 2010 |
Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis.
Topics: Animals; Antioxidants; Aspartate Aminotransferases; Cholagogues and Choleretics; Dietary Fats; Disease Models, Animal; Ethanol; Fatty Acids; Fatty Liver, Alcoholic; gamma-Glutamyltransferase; Glutathione; Lipid Peroxidation; Liver; Male; Microsomes, Liver; Rats; Rats, Wistar; Superoxide Dismutase; Triglycerides; Ursodeoxycholic Acid | 2006 |
Ursodeoxycholate alleviates alcoholic fatty liver damage in rats.
Topics: Animals; Cholagogues and Choleretics; Fatty Liver, Alcoholic; Liver; Male; Membrane Fluidity; Rats; Rats, Sprague-Dawley; Ursodeoxycholic Acid | 1998 |
[Fatty liver].
Topics: Adult; Antioxidants; Cholagogues and Choleretics; Cross-Sectional Studies; Diabetes Complications; Fatty Liver; Fatty Liver, Alcoholic; Humans; Logistic Models; Male; Middle Aged; Obesity; Pilot Projects; Prognosis; Risk Factors; Spain; Ultrasonography; Ursodeoxycholic Acid; Vitamin E | 2000 |
Effect of ursodeoxycholic acid on prostaglandin metabolism and microsomal membranes in alcoholic fatty liver.
Topics: Animals; Cell Polarity; Central Nervous System Depressants; Cholagogues and Choleretics; Dinoprostone; Ethanol; Fatty Acids; Fatty Liver, Alcoholic; Intracellular Membranes; Lipid Metabolism; Male; Microsomes, Liver; Rats; Rats, Wistar; Ursodeoxycholic Acid; Viscosity | 2001 |